Skip to main content

In Brief This Week: Caris Life Sciences, Grifols, LabCorp, and More

NEW YORK – Caris Life Sciences this week said that Montefiore Health System has become the 39th member of the Caris Precision Oncology Alliance, a collaborative network of cancer centers that demonstrate a commitment to precision medicine. Through the alliance, Montefiore will partner with other notable cancer centers and academic institutions to broaden patient access to precision cancer care, have early access to Caris MAI (Molecular Artificial Intelligence) offerings, and establish evidence-based standards for cancer profiling and molecular testing in oncology.


Chicago-based real estate and investment management firm JLL this week announced a collaboration with Laboratory Corporation of America under which LabCorp will provide JLL with COVID-19-related health and wellness services. JLL’s clients will have access to LabCorp Employer Services, which include temperature and symptom screening, PCR testing for SARS-CoV-2, serology testing for coronavirus antibodies, flu vaccinations, and biometric screenings.


Grifols announced this week that it has acquired 10 percent of Bloodbuy, a firm offering a cloud-based marketplace that facilitates the buying and selling of blood components in the US. Bloodbuy’s technology platform and computer-based algorithms enable regional blood-collection centers to expand their customer base, Grifols said. The technology provides access for hospitals and other healthcare providers to vital blood components in an efficient manner.

Bloodbuy’s marketplace is available to qualified hospitals, medical centers, integrated delivery networks, and blood-collection centers. Along with the equity investment, Grifols will obtain a seat on Bloodbuy’s board of directors.


Chromosome Medicina Genômica said this week that it is introducing LifeView PGT-P (Preimplantation Genetic Testing for Polygenic disease) to Brazil in partnership with Genomic Prediction and Diagnosticos da America (DASA). Developed by North Brunswick, New Jersey-based Genomic Prediction, LifeView PGT-P is a genetic screening test that can assess an embryo’s risk of common diseases such as diabetes, common cancers, and heart diseases, and mental disorders such as schizophrenia. Embryos can be screened for one condition, several conditions, or all available conditions which can then be ordered from lowest to highest risk. The method is validated to reduce disease incidence, Genomic Prediction said.


Genetic Technologies this week said it has closed its previously announced direct offering of 1,025,000 American Depositary Shares. Each ADS represents 600 shares of the Australian company’s common stock. At a purchase price of $5 per ADS, the offering raised gross proceeds of about $5.1 million.


PerkinElmer said this week that its board has declared a regular quarterly dividend of $.07 per share of common stock, payable on Nov. 6 to shareholders of record at the close of business on Oct. 16.


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.